ID
44154
Beskrivning
NCT02641314 Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB). The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating immune response, ant-neuroblastic), cyclophosphamide (antiangiogenetic, anti-neuroblastic), etoposide (antiangiogenetic, anti-neuroblastic), and vinblastin (antiangiogenetic, anti-neuroblastic). Vinblastin is scheduled every 14 days intravenously, all other drugs are applied daily throughout 365 days (except etoposide for 4x3 weeks). The efficacies of each of the drugs have been demonstrated in vitro and in vivo in animal studies. All drugs have been used in children for other conditions. From those experiences low toxicities and a favorable Quality of life are expected. Prof. Dr. Frank Berthold Abt. für Kinderonkologie und –hämatologie Zentrum für Kinder- und Jugendmedizin Universität zu Köln
Nyckelord
Versioner (5)
- 2017-12-26 2017-12-26 -
- 2017-12-27 2017-12-27 -
- 2021-03-15 2021-03-15 - Dr. rer. medic Philipp Neuhaus
- 2021-04-13 2021-04-13 - Dr. rer. medic Philipp Neuhaus
- 2021-09-20 2021-09-20 -
Rättsinnehavare
Universität zu Köln
Uppladdad den
20 september 2021
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma (METRO-NB2012) NCT02641314
Study relevant visits
- StudyEvent: Subject Protocol
- Registration
- Medical history
- Baseline
- Therapy and toxicity cycle 1-3
- Therapy and toxicity cycle 4-6
- Therapy and toxicity cycle 7-9
- Therapy and toxicity cycle 10-13
- Therapy and toxicity cycle > 13
- Reference
- Study relevant visits
- Therapeutic response
- End of therapy
- Relapse
- Second malignancy
- Death
- Follow up
Beskrivning
Beurteilung der Lebensqualität
Beskrivning
Surrogatmarker
Beskrivning
undefined item
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0079611
Beskrivning
Collection of blood specimen for laboratory procedure Date in time
Datatyp
date
Måttenheter
- mm/dd/yyyy
Alias
- UMLS CUI [1,1]
- C0178913
- UMLS CUI [1,2]
- C0011008
Beskrivning
Report sent?
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C1524049
- UMLS CUI [1,2]
- C0520510
- UMLS CUI [1,3]
- C0008976
- UMLS CUI [1,4]
- C0205099
Beskrivning
biomarker
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0005516
Beskrivning
Date blood sample
Datatyp
date
Måttenheter
- mm/dd/yyyy
Alias
- UMLS CUI [1,1]
- C0005834
- UMLS CUI [1,2]
- C0011008
Beskrivning
Specimen sent
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C1524049
- UMLS CUI [1,2]
- C0008976
- UMLS CUI [1,3]
- C0205099
Beskrivning
Batch
Datatyp
boolean
Alias
- UMLS CUI [1]
- C3641829
Beskrivning
Shipping date in time
Datatyp
date
Måttenheter
- mm/dd/yyyy
Alias
- UMLS CUI [1,1]
- C0370003
- UMLS CUI [1,2]
- C1524049
- UMLS CUI [1,3]
- C0011008
Beskrivning
Bemerkung
Similar models
Study relevant visits
- StudyEvent: Subject Protocol
- Registration
- Medical history
- Baseline
- Therapy and toxicity cycle 1-3
- Therapy and toxicity cycle 4-6
- Therapy and toxicity cycle 7-9
- Therapy and toxicity cycle 10-13
- Therapy and toxicity cycle > 13
- Reference
- Study relevant visits
- Therapeutic response
- End of therapy
- Relapse
- Second malignancy
- Death
- Follow up
C0392360 (UMLS CUI [1,2])
C0034380 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0520510 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
C0205099 (UMLS CUI [1,4])
C0011008 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,2])
C0205099 (UMLS CUI [1,3])
C1524049 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])